Visible-Light-Triggered Prodrug Nanoparticles Combine Chemotherapy and Photodynamic Therapy to Potentiate Checkpoint Blockade Cancer Immunotherapy

  • ACS Nano. 2021 Jul 27;15(7):12086-12098. doi: 10.1021/acsnano.1c03416.
Jiwoong Choi  1  2 Man Kyu Shim  2 Suah Yang  1  2 Hee Sook Hwang  3 Hanhee Cho  2 Jeongrae Kim  1  2 Wan Su Yun  1  2 Yujeong Moon  2  4 Jinseong Kim  1  2 Hong Yeol Yoon  2 Kwangmeyung Kim  1  2
Affiliations
  • 1. KU-KIST Graduate School of Converging Science and Technology, Korea University, Seoul 02841, Republic of Korea.
  • 2. Biomedical Research Institute, Korea Institute of Science and Technology (KIST), Seoul 02792, Republic of Korea.
  • 3. Department of Pharmaceutical Engineering, Dankook University, Cheonan 31116, Republic of Korea.
  • 4. Department of Bioengineering, Korea University, Seoul 02841, Republic of Korea.
Abstract

Immune checkpoint blockade is a promising approach for Cancer Immunotherapy, but many patients do not respond due to the immunosuppressive tumor microenvironment (ITM). Herein, we propose visible-light-triggered prodrug nanoparticles (LT-NPs) for reversing ITM into high immunogenic tumors to potentiate checkpoint blockade immunotherapy. The Photosensitizer (verteporfin; VPF), cathepin B-specific cleavable peptide (FRRG), and doxorubicin (DOX) conjugates are self-assembled into LT-NPs without any additional carrier material. The LT-NPs are specifically cleaved to VPF and DOX in Cathepsin B-overexpressing Cancer cells, thereby inducing cancer-specific cytotoxicity and immunogenic cell death (ICD) upon visible light irradiation. In tumor models, LT-NPs highly accumulate within tumors via the enhanced permeability and retention effect, and photochemotherapy of VPF and DOX induces effective ICD and maturation of dendritic cells to stimulate cross-presentation of cancer-antigens to T cells. Furthermore, LT-NPs with PD-L1 blockade greatly inhibit tumor growth, tumor recurrence, and lung metastasis by initiating a strong antitumor immune response. The photochemotherapy by LT-NPs provides a promising strategy for effective checkpoint blockade immunotherapy.

Keywords
antitumor immune response; cancer immunotherapy; immune checkpoint blockade; light-triggered prodrug; photochemotherapy.
Products